Headlines about Nuvectra (NASDAQ:NVTR) have been trending somewhat negative recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nuvectra earned a daily sentiment score of -0.02 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9504851139178 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of equities research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Piper Jaffray Companies reissued a “hold” rating and issued a $12.00 price target on shares of Nuvectra in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $12.00.
Nuvectra (NASDAQ NVTR) traded up $0.16 during trading on Friday, hitting $8.81. 36,800 shares of the stock were exchanged, compared to its average volume of 112,867. The stock has a market cap of $93.28, a P/E ratio of -1.87 and a beta of -0.77. Nuvectra has a twelve month low of $5.76 and a twelve month high of $15.00. The company has a quick ratio of 2.72, a current ratio of 2.90 and a debt-to-equity ratio of 0.37.
Nuvectra (NASDAQ:NVTR) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.07. The business had revenue of $7.60 million for the quarter, compared to the consensus estimate of $8.08 million. Nuvectra had a negative net margin of 204.19% and a negative return on equity of 68.63%. The business’s revenue was up 100.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.92) EPS. equities research analysts forecast that Nuvectra will post -4.58 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was first reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.truebluetribune.com/2018/01/19/somewhat-critical-news-coverage-somewhat-unlikely-to-impact-nuvectra-nvtr-share-price.html.
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.